* To be consumed as directed by physician.
Tocira 400Mg Injection
Each vial contains 400 mg of Tocilizumab in 20 mL (20 mg/mL)
Tocilizumab is a recombinant humanized anti-human interleukin 6 (IL-6) receptor monoclonal antibody of the immunoglobulin IgG1k (gamma 1, kappa) subclass with a typical H2L2 polypeptide structure. Each light chain and heavy chain consists of 214 and 448 amino acids, respectively. The four polypeptide chains are linked intra- and inter-molecularly by disulfide bonds. Tocilizumab has a molecular weight of approximately 148 kDa. The antibody is produced in mammalian (Chinese hamster ovary) cells.
Concentrate for solution for infusion (sterile concentrate). Clear to opalescent, colourless to pale yellow solution.
The recommended dosage for emergency use of Tocilizumab authorized under this EUA given as a single 60-minute intravenous infusion is:
| Recommended Intravenous Dosage for COVID-19 | |
|---|---|
| Patients at or above 30 kg weight | 8 mg/kg |
If clinical signs or symptoms worsen or do not improve after the first dose, one additional infusion of Tocilizumab may be administered at least 8 hours after the initial infusion.
Maximum Dosage in COVID-19 patients is 800 mg per infusion.
Tocilizumab subcutaneous administration is not authorized for the treatment of COVID-19 patients.
Tocilizumab is indicated for restricted use of the drug under emergency situation in the country to treat COVID-19 hospitalized adults who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Product Enquiry
